FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

https://pub.webull.com/us/news-html/2ed53ac64a2d4c70a7abbc5cb8a22fbf.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en&theme=1 FibroGen Inc (NASDAQ:FGEN) is a total spec and earnings won't matter, said Cramer. He likes the idea as long as investors put the stock in the total speculative column.

https://www.globenewswire.com/news-release/2020/10/22/2112965/0/en/FibroGen-Presents-Late-Breaker-Abstract-Results-on-Associations-between-Hemoglobin-Levels-and-Cardiovascular-Outcomes-in-Roxadustat-Treated-Patients-with-Anemia-of-Chronic-Kidney-D.html

https://endpts.com/akebia-shares-crater-as-their-phiii-anemia-drug-fails-on-safety-offering-rival-fibrogen-a-huge-advantage/ Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

https://www.globenewswire.com/news-release/2020/08/11/2076245/0/en/FibroGen-Announces-First-Patient-Enrolled-in-Pamrevlumab-Phase-3-Clinical-Trial-in-Patients-with-Duchenne-Muscular-Dystrophy.html

Huiii ✌️

*** = investing_

Mizuho Securities Stick to Their Buy Rating for FibroGen https://www.***/news/mizuho-securities-stick-to-their-buy-rating-for-fibrogen-2258082 ...setting a price target of 72, which is approximately 68.82% above the present share price of 42.65. ...

Bzw kurz: https://seekingalpha.com/news/3602426-fibrogen-eps-misses-0_39-misses-on-revenue FibroGen EPS misses by $0.39, misses on revenue FibroGen (NASDAQ:FGEN): Q2 GAAP EPS of -$0.95 misses by $0.39. Revenue of $42.89M (-77.6% Y/Y) misses by $5.4M.

https://www.globenewswire.com/news-release/2020/08/06/2074568/0/en/FibroGen-Reports-Second-Quarter-2020-Financial-Results.html FibroGen Reports Second Quarter 2020 Financial Results

https://www.globenewswire.com/news-release/2020/06/23/2051872/0/en/FibroGen-Announces-First-Patient-Enrolled-in-Pamrevlumab-Clinical-Trial-in-Patients-Hospitalized-in-U-S-with-Acute-COVID-19.html FibroGen gibt den ersten Patienten bekannt, der an einer klinischen Pamrevlumab-Studie bei Patienten mit akutem COVID-19 in den USA teilnimmt

👍👍👍

http://www.globenewswire.com/news-release/2020/06/22/2051107/0/en/FibroGen-Appoints-Thane-Wettig-as-Chief-Commercial-Officer.html

https://www.globenewswire.com/news-release/2020/06/08/2044807/0/en/FibroGen-Announces-First-Patient-Enrolled-in-Pamrevlumab-Clinical-Trial-in-Patients-Hospitalized-in-Italy-with-Severe-COVID-19.html

Yees ✌️

Die Europäische Arzneimittel-Agentur (EMA) nimmt den Marketingantrag von Astellas Pharma (OTCPK: ALPMF) zur Genehmigung von Roxadustat zur Behandlung von Anämie bei erwachsenen Patienten mit chronischer Nierenerkrankung zur Überprüfung an. Die Aktion löst eine Meilensteinzahlung in Höhe von 130 Mio. USD an den Lizenzgeber FibroGen (NASDAQ: FGEN) aus.

https://www.ptcommunity.com/wire/european-medicines-agency-accepts-astellas-marketing-authorization-application-roxadustat ... Die Akzeptanz des Roxadustat MAA durch die EMA zur Behandlung von Anämie bei erwachsenen Patienten mit CNI unter Dialyse und nicht unter Dialyse löst eine Meilensteinzahlung von 130 Millionen US-Dollar durch Astellas an FibroGen aus.